Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients
Summary
- Most common reasons to modify a virologically suppressive boosted PI–containing regimen are gastrointestinal adverse effects (nausea and diarrhea), high cardiovascular risk, dyslipidemia, pharmacologic interactions with ritonavir, and regimen simplification (less-frequent dosing, lower pill burden)
- HIV-infected patients experiencing adverse events associated with the use of ritonavir have switch options that include a lower dose of ritonavir (Table 4)
- Some patients receiving atazanavir and low-dose ritonavir who experience adverse events may be successfully switched to unboosted atazanavir
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content